Company Research Report: ElevateBio

Company Overview

Name

ElevateBio

Mission of the Company

Powering the creation of life-transforming cell and gene therapies at a speed the world deserves.

Founding Details

Founded in: 2017

Founded by: David Hallal, Mitchell Finer, and Vikas Sinha

Key People

David Hallal: Chief Executive Officer & Chairman

Mitchell H. Finer, Ph.D.: Strategic Advisor

Vikas Sinha, MBA: Chief Financial Officer

Jacob Abrams: General Counsel

Bhakti Bhargava, MBA: SVP, Head of Finance & Accounting

Tedd Elich, Ph.D.: Chief Scientific Officer of Life Edit

Catherine Hu: SVP, Corporate Affairs & Investor Relations

Katie Jorgensen: VP, Site Head, BaseCamp

Tess Kitchener: VP, BaseCamp BD Manufacturing

Missy Kotchey: SVP, Head of People & Culture

Amit Mathur, MBA: SVP, Chief Information Officer

Clare Murray, Ph.D., MBA: SVP, Corporate Development & Operations of Life Edit

Aaron Nudelman, Ph.D., J.D.: SVP, Head of Intellectual Property

Michael Paglia, M.S.: Chief Technology Officer of BaseCamp

Heidi Wagner, J.D.: Global Head of Government Affairs

Headquarters

Waltham, MA

Number of Employees

No information is available.

Revenue

No information is available.

Known For

Being a technology-driven genetic medicines company, accelerating access to cutting-edge technologies, end-to-end manufacturing capabilities, and expertise in cell and gene therapies.

Products

Overview

ElevateBio provides advanced products and solutions in the field of gene and cell therapies with an emphasis on integrated technology platforms.

Key Products and Technologies

1. BaseCamp®

Description: State-of-the-art genetic medicine current Good Manufacturing Practice (cGMP) manufacturing and process development business.

Key Features: Provides end-to-end capabilities from concept to commercialization, including viral vector and cell therapy centers of excellence.

2. LentiPeak™ Platform

Description: A proprietary lentiviral vector production platform.

Key Features: Customizable for suspension-based, scalable production, accelerating transition from preclinical to clinical development, and reducing manufacturing costs.

3. Gene Editing Platforms

Description: Suite of powerful gene editing technologies.

Key Features: Includes double-strand breaks, base editing, and reverse transcriptase editing with both viral and non-viral delivery platforms.

4. Cell Therapy Enabling Technologies

Key Features: Supports development across process development, analytical development, CMC regulatory, manufacturing, and more for autologous and allogeneic therapies.

5. RNA Engineering Platforms

Features: Facilitate the development of next-generation cell and gene therapies through RNA, protein, and vector engineering technologies.

Recent Developments

Advancements and Innovations

October 16, 2024: Announced advancements in its Proprietary Lipid Nanoparticle (LNP) Delivery Platform with liver targeting and de-targeting potential.

May 14, 2024: Secured new U.S. patents for Lead Life Edit CRISPR Systems and Adenine Deaminases, enabling advanced gene editing techniques.

Partnerships and Collaborations

May 24, 2023: Life Edit Therapeutics and Novo Nordisk established a multi-target collaboration for developing gene editing therapies for rare and cardiometabolic diseases.

February 22, 2023: Partnership with Moderna to accelerate novel in vivo gene editing therapies.

September 26, 2023: Collaboration with Kyverna Therapeutics to advance cell therapy manufacturing.

Financial Developments

May 24, 2023: Closed a $401 million Series D financing to further accelerate growth.

New Product Developments

November 3, 2022: Unveiled the LentiPeak™ Lentiviral Vector Platform.

Strategic Initiatives

April 22, 2024: Presented at the American Society of Gene and Cell Therapy (ASGCT) 27th Annual Meeting.

Employment and Leadership

March 7, 2023: Appointed Heidi L. Wagner, J.D., as Global Head of Government Affairs.

Overall, ElevateBio remains focused on leveraging its comprehensive ecosystem of technologies and capabilities to not only develop its own pipeline of therapeutics but also support a growing number of biopharmaceutical partners in advancing the field of genetic medicines.